Nourish and CABIO partner to bring animal-free fat Tastilux to Chinese market - SmartCompany
| 688089 Stock | 18.09 0.25 1.40% |
About 51% of Cabio Biotech's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Cabio Biotech Wuhan suggests that some traders are interested. The current market sentiment, together with Cabio Biotech's historical and current headlines, can help investors time the market. In addition, many technical investors use Cabio Biotech Wuhan stock news signals to limit their universe of possible portfolio assets.
Cabio |
Nourish and CABIO partner to bring animal-free fat Tastilux to Chinese market SmartCompany
Read at news.google.com
 |
Cabio Biotech Fundamental Analysis
We analyze Cabio Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cabio Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cabio Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Cabio Biotech is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Cabio Biotech Wuhan Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cabio Biotech stock to make a market-neutral strategy. Peer analysis of Cabio Biotech could also be used in its relative valuation, which is a method of valuing Cabio Biotech by comparing valuation metrics with similar companies.
Peers
Cabio Biotech Related Equities
| 603269 | Jiangsu Seagull | 9.96 | ||||
| 002999 | Guangdong Tianhe | 0.72 | ||||
| 300243 | Shandong Ruifeng | 0.67 | ||||
| 300729 | Loctek Ergonomic | 0.07 | ||||
| 002096 | Hunan Nanling | 0.53 | ||||
| 601615 | Ming Yang | 2.94 | ||||
| 002952 | Yes Optoelectronics | 10.01 |
Complementary Tools for Cabio Stock analysis
When running Cabio Biotech's price analysis, check to measure Cabio Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cabio Biotech is operating at the current time. Most of Cabio Biotech's value examination focuses on studying past and present price action to predict the probability of Cabio Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cabio Biotech's price. Additionally, you may evaluate how the addition of Cabio Biotech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |